{"entity":{"id":"nct06550141","kind":"trial","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","aka":[],"tldr":"A phase 2 trial of Emapalumab, Cyclophosphamide, Fludarabine and Axicabtagene ciloleucel in Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Primary mediastinal and Follicular lymphoma, run by Marcela V. Maus, M.D.,Ph.D., now recruiting.","summary":"Emapalumab Prevention of CAR-T Cell Associated Toxicities is a phase 2 interventional study registered as NCT06550141 by Marcela V. Maus, M.D.,Ph.D., with 28 participants planned, started 2024-09-18 and due to reach its primary completion in 2026-08-01. Interventions recorded: Emapalumab, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel. Conditions recorded: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma.\n\nLinked to the drug Emapalumab because the registry names it among its interventions and Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Primary mediastinal and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06550141","url":"https://clinicaltrials.gov/study/NCT06550141"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","dlbcl","primary-mediastinal-b-cell-lymphoma","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["emapalumab","cyclophosphamide","fludarabine","axicabtagene-ciloleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06550141","phase":"2","setting":"A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities","sponsor":"Marcela V. Maus, M.D.,Ph.D.","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06550141/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}